Literature DB >> 2319164

Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children.

L J Anderson1, R A Parker, R L Strikas.   

Abstract

The temporal patterns of respiratory virus isolations from 10 laboratories in the USA were compared with that of deaths of children less than 5 years old from July 1975 through June 1984. Isolations of respiratory syncytial virus (RSV) occurred as yearly winter outbreaks; parainfluenza virus 1 and 2 isolations occurred as well-defined outbreaks every other year in the autumn; parainfluenza virus 3 isolations occurred throughout the year with periodic, increased isolations suggestive of outbreaks; and influenza virus isolations (A, B, or A plus B) occurred as yearly winter outbreaks. After data were controlled for seasonal patterns, RSV isolations were strongly correlated with the winter peaks in lower respiratory tract illness (LRI) deaths of infants 1-11 months old; influenza virus isolations were correlated with the winter peak in LRI deaths of children 24-59 months old. The parainfluenza viruses were not correlated with respiratory deaths. This study supports the idea that RSV is a major contributor to winter peaks in LRI deaths of children 1-11 months old.

Entities:  

Mesh:

Year:  1990        PMID: 2319164     DOI: 10.1093/infdis/161.4.640

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.

Authors:  Dan Yan; Stefanie A Krumm; Aiming Sun; David A Steinhauer; Ming Luo; Martin L Moore; Richard K Plemper
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

3.  Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex.

Authors:  Alberto Jiménez-Somarribas; Shuli Mao; Jeong-Joong Yoon; Marco Weisshaar; Robert M Cox; Jose R Marengo; Deborah G Mitchell; Zachary P Morehouse; Dan Yan; Ivan Solis; Dennis C Liotta; Michael G Natchus; Richard K Plemper
Journal:  J Med Chem       Date:  2017-03-13       Impact factor: 7.446

4.  Complete genome sequence of human respiratory syncytial virus genotype A with a 72-nucleotide duplication in the attachment protein G gene.

Authors:  Wan-Ji Lee; You-jin Kim; Dae-Won Kim; Han Saem Lee; Ho Yeon Lee; Kisoon Kim
Journal:  J Virol       Date:  2012-12       Impact factor: 5.103

Review 5.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

Review 6.  Bronchiolitis. Origins and optimal management.

Authors:  M L Everard
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

7.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

8.  Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.

Authors:  Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

9.  Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents.

Authors:  Susanne Meury; Sven Zeller; Ulrich Heininger
Journal:  Eur J Pediatr       Date:  2004-04-23       Impact factor: 3.183

10.  Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

Authors:  H C Meissner; D R Fulton; J R Groothuis; R L Geggel; G R Marx; V G Hemming; T Hougen; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.